What Is a Typical MDMA Dosage?

A typical MDMA dose falls in the range of about 75 to 125 milligrams taken orally, with clinical research trials generally using 125 mg as a standard therapeutic dose. That single number, though, hides a lot of important nuance. MDMA’s effects scale steeply with dose, individual biology plays a surprisingly large role in how a given amount hits, and the common practice of re-dosing introduces its own set of complications. Understanding the dose range matters because MDMA does not behave the way most people assume when the amount goes up even slightly.

The Clinical Benchmark

The most carefully controlled data on MDMA dosing comes from psychotherapy research. In clinical trials studying MDMA-assisted therapy for treatment-resistant PTSD, patients received an initial dose of 125 mg followed about two hours later by a supplemental dose of 62.5 mg.¹ That 125 mg figure was chosen after earlier phases tested lower amounts and found that dose range reliably produced the desired psychological effects without pushing physiological responses into dangerous territory for medically screened participants under supervision.

These trials provide the closest thing to a scientifically validated “standard dose.” Participants were healthy enough to pass medical screening, sessions were conducted with blood pressure monitoring and medical staff on hand, and the MDMA itself was pharmaceutical-grade with a known purity. None of those conditions apply in recreational settings, which is one reason clinical dosing numbers cannot simply be copied as safe guidelines for unsupervised use.

What Happens in Your Body at a Standard Dose

At doses in the clinical range, MDMA reliably raises heart rate, blood pressure, and subjective feelings of energy and emotional closeness. A controlled study administering oral MDMA found dose-dependent increases in heart rate reaching as high as 132 beats per minute, systolic blood pressure peaking at 171 mmHg, and diastolic blood pressure hitting 102 mmHg.² Participants also reported heightened senses, feelings of closeness to others, and a sense of being “high.” The study found no significant changes in body temperature, respiratory rate, or blood oxygen levels at the doses tested.

Those blood pressure and heart rate numbers are worth pausing on. A systolic reading of 171 is in the hypertensive crisis range for someone whose resting blood pressure is already elevated. For a young, healthy person with normal baseline blood pressure, that spike is temporary and generally tolerable. For someone with undiagnosed high blood pressure or a heart condition, the same spike could be genuinely dangerous. The dose that produces a manageable cardiovascular response in one person can produce an alarming one in another, even when the milligram amount is identical.

Why Small Dose Increases Matter More Than You Think

One of the most important and least understood aspects of MDMA dosing is that the drug does not follow a simple “twice the dose, twice the effect” relationship. MDMA has what pharmacologists call non-linear pharmacokinetics, meaning that a modest bump in the amount you take produces a disproportionately large jump in the drug’s concentration in your blood. A study examining this phenomenon across a range of recreational-level doses found that this non-linearity applies to the general population regardless of genetic differences in how people metabolize the drug.³

In practical terms, this means the difference between 100 mg and 150 mg is not a 50% increase in effect. The blood levels of MDMA jump by much more than 50%, which makes the person considerably more vulnerable to acute toxicity. People sometimes think of dosing as a dial they can turn smoothly from mild to strong, but it behaves more like a dial that suddenly lurches at certain points. This non-linear behavior is one of the main reasons that people who have taken MDMA several times at one dose can run into serious trouble the first time they take just a little more.

The practical lesson here is that eyeballing a slightly larger dose, splitting a pill unevenly, or taking an unknown-strength tablet that happens to contain more than expected can shift someone from a manageable experience to a medical emergency in a way that feels completely out of proportion to the amount consumed.

Re-Dosing and Booster Doses

Taking a second, smaller dose partway through an experience is common both in clinical settings and in recreational use. The clinical protocol mentioned earlier uses a 62.5 mg booster about two hours after the initial 125 mg dose. A controlled study comparing MDMA sessions with and without a booster found that the supplemental dose extended the duration of subjective effects by roughly an hour, from about 4.6 hours to about 5.6 hours on average, without increasing the peak intensity of either the subjective high or the cardiovascular response.⁴

That finding is useful because it clarifies what a booster actually does and does not do. A properly timed, appropriately sized supplemental dose prolongs the experience without making it more intense. The key variables are the size and timing. The clinical booster is half the original dose, taken at a specific window. Recreational re-dosing often looks very different: people take a second full dose, or they re-dose multiple times, or they re-dose late in the experience when the first dose is wearing off and they want to recapture the peak. Each of those patterns adds risk that the controlled booster protocol was designed to avoid, and the non-linear pharmacokinetics described above make repeated or large re-doses especially unpredictable.

Why the Same Dose Hits People Differently

Body weight is the most obvious factor. Someone who weighs 55 kg will have higher blood concentrations of MDMA from the same milligram dose than someone who weighs 90 kg. Many harm-reduction sources suggest a rough guideline of about 1 to 1.5 mg per kilogram of body weight, though this is a rule of thumb rather than a clinically established formula. Even adjusted for weight, though, people vary widely in how they respond.

A major source of that variation is genetic. The liver enzyme CYP2D6 is primarily responsible for breaking down MDMA, and the gene encoding it comes in dozens of variants across the human population. Some people are “poor metabolizers” who break down MDMA slowly, leading to higher and longer-lasting blood levels from the same dose. Others are “ultrarapid metabolizers” who clear it quickly. A pooled analysis of eight controlled studies involving 139 healthy participants confirmed that CYP2D6 genetic variants significantly affect both how much MDMA ends up in the bloodstream and how strongly a person feels its effects.⁵

What makes this tricky is that most people have no idea what their CYP2D6 status is. You can find out through pharmacogenomic testing, but very few recreational users have done that. The practical upshot is that two people of similar weight can take the same pill and have meaningfully different experiences, not because one is “more sensitive” in some vague way, but because their livers process the drug at genuinely different rates. This also interacts with the non-linear pharmacokinetics: a slow metabolizer effectively behaves as though they took a larger dose, and because the dose-response curve is steep, even a modest difference in metabolism can translate to a significant difference in blood concentration and risk.³

Sex differences also play a role. Women tend to have higher MDMA blood levels than men after the same weight-adjusted dose, partly because of body composition differences and partly because women are more likely to carry CYP2D6 variants associated with slower metabolism. This does not mean women cannot tolerate MDMA, but it does mean that a dose considered moderate for a larger man can be a high dose for a smaller woman.

The Hyponatremia Problem

One of the most dangerous complications of MDMA use has little to do with the dose being “too high” in the traditional sense. MDMA-induced hyponatremia, a dangerous drop in blood sodium levels to below 120 millimoles per liter, can occur after even a single standard dose. The condition typically develops several hours after ingestion and can cause seizures, cerebral edema, and rising pressure inside the skull.⁶

The mechanism involves two things happening at once. MDMA triggers the release of antidiuretic hormone, which tells the kidneys to hold onto water instead of excreting it. At the same time, users in warm environments who are dancing or exerting themselves often drink large amounts of water because of widespread advice to “stay hydrated” while using MDMA. The combination of water retention and excessive water intake dilutes blood sodium to dangerous levels. The irony is that the very behavior people adopt to stay safe, drinking lots of water, can become the primary threat.

Hyponatremia is more common in women, partly because of hormonal interactions with antidiuretic hormone and partly because of smaller body size meaning less total body water to dilute. Emergency departments have documented fatal cases in otherwise healthy young women who took amounts of MDMA that their friends tolerated without visible problems. The dose in these cases was not necessarily extreme; the complication arose from the body’s hormonal response to the drug combined with fluid intake behavior.

Sensible fluid intake during MDMA use means sipping modest amounts rather than gulping water continuously. If you are not exerting yourself, you need less fluid than you think. Electrolyte-containing drinks are preferable to plain water when you are drinking to replace sweat loss, because they help maintain sodium balance.

Why Street Doses Are Unpredictable

Everything discussed above assumes you know how many milligrams you are taking. In practice, that is rarely the case outside a clinical trial. Pressed tablets sold as “ecstasy” have been found to contain anywhere from 50 mg to over 300 mg of MDMA, and some contain no MDMA at all, substituting other stimulants, cathinones, or synthetic compounds. Crystal or powder MDMA (“molly”) is often assumed to be purer, but testing services routinely find adulterants or entirely different substances.

This uncertainty interacts badly with everything else. If a tablet contains 200 mg and someone takes the whole thing thinking it is a standard dose, the non-linear pharmacokinetics mean they are not just getting roughly double the effect of a 100 mg dose. They are getting considerably more than double the blood concentration, with correspondingly amplified cardiovascular strain and toxicity risk. Add in unknown CYP2D6 status and the possibility of a slow metabolizer taking a high-content pill, and the margin between a strong experience and a hospital visit narrows considerably.

Drug-checking services, where available, can identify the substance and approximate the dose in a tablet. Reagent testing kits sold for home use can confirm the presence of MDMA but cannot tell you how many milligrams are in a pill. For people who choose to use MDMA despite the risks, knowing the actual content of what you are taking is probably the single most impactful harm-reduction step, because it is the one variable that determines whether all the clinical dose-range data is even relevant to your situation.

How Tolerance Develops

People who use MDMA repeatedly over a short period often find that the same dose produces weaker effects. This is partly because MDMA works by flooding the brain with serotonin, and the supply of available serotonin takes time to replenish after a large release. Taking MDMA again before stores have recovered means there is less serotonin to release, so the subjective experience is blunted even though the cardiovascular and neurotoxic effects continue at the same level or higher.

This creates a dangerous mismatch. The psychological experience feels weaker, tempting the user to take more, while the physiological burden on the heart, liver, and brain stays just as heavy or gets heavier because of the non-linear dose-response. People chasing a diminished high by escalating their dose are climbing the steepest part of the toxicity curve while getting less of the experience they are trying to recapture. The common wisdom that MDMA “loses its magic” with frequent use reflects real neuropharmacology, and the instinct to compensate with higher doses is one of the more reliable routes to acute harm.

Most harm-reduction guidance suggests waiting at least several weeks between uses to allow serotonin levels to recover. This is not just about preserving the quality of the experience; it is about keeping the dose-to-risk ratio in a range where the drug’s effects are at least somewhat predictable.